Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.


• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities


Press Release

Berlin, Germany

2019, February 01
8:00 a.m.

New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer

2019, January 14
6:00 p.m.

Half-yearly report on the liquidity contract with Invest Securities

2019, January 04
8:00 a.m.

Results of NOXXON's extra-ordinary general meeting of shareholders


Aram Mangasarian
Feb 06-08, New York City, NY, USA

Aram Mangasarian
Mar 25-27, Vienna, Austria

Aram Mangasarian, Jarl Ulf Jungnelius
Mar 29 - Apr 03, Atlanta, GA, USA